Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats

KB Dupre, CY Ostock, KLE Jaunarajs, T Button… - Experimental …, 2011 - Elsevier
Serotonin 1A receptor (5-HT 1A R) agonists reduce both l-DOPA- and D1 receptor (D1R)
agonist-mediated dyskinesia, but their anti-dyskinetic mechanism of action is not fully …

Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat

KLE Jaunarajs, KB Dupre, CY Ostock… - Behavioural …, 2010 - journals.lww.com
Depression and anxiety are the prevalent nonmotor symptoms that worsen quality of life for
Parkinson's disease (PD) patients. Although dopamine (DA) cell loss is a commonly …

Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats

MM Conti, CY Ostock, D Lindenbach, AA Goldenberg… - …, 2014 - Elsevier
Dopamine (DA) replacement therapy with l-DOPA is the standard treatment for Parkinson's
disease (PD). Unfortunately chronic treatment often leads to the development of abnormal …

Side effect profile of 5‐HT treatments for P arkinson's disease and L‐DOPA‐induced dyskinesia in rats

D Lindenbach, N Palumbo, CY Ostock… - British journal of …, 2015 - Wiley Online Library
Background and Purpose Treatment of P arkinson's disease ( PD ) with L ‐ DOPA
eventually causes abnormal involuntary movements known as dyskinesias in most patients. …

Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation

CY Ostock, KB Dupre, KLE Jaunarajs, H Walters… - …, 2011 - Elsevier
While serotonin 5-HT1A receptor (5-HT1AR) agonists reduce l-DOPA-induced dyskinesias (LID)
by normalizing activity in the basal ganglia neurocircuitry, recent evidence suggests …

The role of primary motor cortex (M1) glutamate and GABA signaling in l-DOPA-induced dyskinesia in parkinsonian rats

D Lindenbach, MM Conti, CY Ostock… - Journal of …, 2016 - Soc Neuroscience
Long-term treatment of Parkinson's disease with l-DOPA almost always leads to the
development of involuntary movements termed l-DOPA-induced dyskinesia. Whereas …

Behavioral and cellular modulation of l-DOPA-induced dyskinesia by β-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat

D Lindenbach, CY Ostock, KLE Jaunarajs… - … of Pharmacology and …, 2011 - ASPET
Chronic dopamine replacement therapy in Parkinson's disease (PD) leads to deleterious
motor sequelae known as l-DOPA-induced dyskinesia (LID). No known therapeutic can …

Diverse serotonin actions of vilazodone reduce l‐3, 4‐dihidroxyphenylalanine–induced dyskinesia in hemi‐parkinsonian rats

…, NE Chambers, Y Avnor, CY Ostock… - Movement …, 2018 - Wiley Online Library
Background: The serotonergic system is a well‐established modulator of l‐dopa‐induced
dyskinesia. To date, targeting serotonin transporters or serotonin receptor subtype 1A (5‐HT …

Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus

CY Ostock, J Hallmark, N Palumbo, N Bhide, M Conti… - …, 2015 - Elsevier
Long-term l-DOPA use for Parkinson's disease (PD) is frequently complicated by the
emergence of a debilitating motor side effect known as l-DOPA-induced dyskinesia (LID). …

Effects of 5-HT1A Receptor Stimulation on D1 Receptor Agonist-Induced Striatonigral Activity and Dyskinesia in Hemiparkinsonian Rats

KB Dupre, CY Ostock, JA George… - ACS chemical …, 2013 - ACS Publications
Accumulating evidence supports the value of 5-HT 1A receptor (5-HT 1A R) agonists for
dyskinesias that arise with long-term L-DOPA therapy in Parkinson’s disease (PD). Yet, how 5-…